Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18604163 | 0.91 | DNM1 (0.50) | DNM1TSHRTHRBBDKRB2LMNA | |
| SCHEMBL18604043 | 0.91 | DNM1 (0.50) | DNM1TSHRTHRBBDKRB2LMNA | |
| SCHEMBL2837712 | 0.91 | DNM1 (0.52) | DNM1TSHRBDKRB2FDPS | |
| Thiocyanic Acid SCHEMBL3782992 | 0.81 | DNM1 (0.67) | DNM1TSHRTHRBBDKRB2LMNA | |
| SCHEMBL15212451 | 0.80 | TSHR (0.33) | DNM1TSHR | |
| SCHEMBL30998859 | 0.80 | DNM1 (0.93) | DNM1TSHRTHRBBDKRB2LMNA | |
| SCHEMBL31351285 | 0.80 | DNM1 (0.93) | DNM1TSHRTHRBBDKRB2LMNA | |
| SCHEMBL29616053 | 0.80 | DNM1 (0.93) | DNM1TSHRTHRBBDKRB2LMNA | |
| SCHEMBL31741195 | 0.80 | DNM1 (0.93) | DNM1TSHRTHRBBDKRB2LMNA | |
| SCHEMBL29616035 | 0.80 | DNM1 (0.93) | DNM1TSHRTHRBBDKRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY INC (US) | 2021-12-23 | — | — | US | claimed |
| US-20130341561-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY, INC. (US) | 2013-12-26 | — | — | US | claimed |
| EP-2279172-B1 | USE OF IONIC LIQUIDS WITH TETRACYANOBORATE ANIONS AS A SOLVENT FOR EXTRACTION OF ALCOHOLS FROM AQUEOUS SOLUTIONS | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | claimed |
| US-8455703-B2 | Use of ionic liquids with tetracyanoborate anions as a solvents for extraction of alcohols from aqueous solutions | MERCK PATENT GMBH (DE) | 2013-06-04 | — | — | US | claimed |
| US-20110071324-A1 | Use of ionic liquids with tetracyanoborate anions as a solvents for extraction of alcohols from aqueous solutions | MERCK PATENT GESELLSCHAFT (DE) | 2011-03-24 | — | — | US | claimed |
| US-7718579-B2 | Electrochemical deblocking using a hydrazine derivative | COMBIMATRIX CORPORATION (US) | 2010-05-18 | — | — | US | claimed |
| EP-1869061-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | Combimatrix Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| EP-1805206-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | Combimatrix Corporation (US) | 2007-07-11 | — | — | EP | claimed |
| US-20070034513-A1 | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array | COMBIMATRIX CORPORATION | 2007-02-15 | — | — | US | claimed |
| WO-2006105037-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | COMBIMATRIX CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| WO-2006031814-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | COMBIMATRIX CORPORATION (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060054511-A1 | Electrochemical deblocking using a hydrazine derivative | CUSTOMARRAY, INC. | 2006-03-16 | — | — | US | claimed |
| US-20240101999-A1 | HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS | THERMO FISHER SCIENTIFIC GENEART GMBH (DE) | 2024-03-28 | — | — | US | disclosed |
| CN-115927293-A | Efficient small volume nucleic acid synthesis | 生命技术公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-107532129-B | Efficient small volume nucleic acid synthesis | 生命技术公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3557262-B1 | HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS | LIFE TECHNOLOGIES CORP (US) | 2022-08-10 | — | — | EP | disclosed |
| US-20070034513-A1 | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array | COMBIMATRIX CORPORATION | 2007-02-15 | — | — | US | disclosed |
| WO-2006105037-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | COMBIMATRIX CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006031814-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | COMBIMATRIX CORPORATION (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060054511-A1 | Electrochemical deblocking using a hydrazine derivative | CUSTOMARRAY, INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | DNMT1, DNASE1, DNPEP | DNM1 649/4885TSHR 2247/4885THRB 1797/4885 |
| US-20110071324-A1 | Use of ionic liquids with tetracyanoborate anions as a solvents for extraction of alcohols from aqueous solutions | ADH1C, SLC6A6, ADH5 | DNM1 3835/4885TSHR 1268/4885THRB 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.